The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced it will award US$2 million to Immunethep SA to develop a conjugated peptide-based vaccine to prevent ...

Department of Health and Human Services Secretary Robert F. Kennedy Jr. paused a $240 million contract to create a new coronavirus vaccine.

Yale researchers have found "differences in immune profiles" among those who struggle with negative reactions to the Covid ...

FDA's reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent ...

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...